BioMarin, Alliant announce FDA approval of asthma medication Orapred ODT

By Elaine Rigoli

Tampa, Fla., June 1 - BioMarin Pharmaceutical, Inc. and Alliant Pharmaceuticals, Inc. said the Food and Drug Administration has granted marketing approval for Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets), the first orally disintegrating tablet form of prednisolone available in the United States.

Alliant said it expects to begin marketing Orapred ODT in the United States in August or September.

The Orapred product line, which includes Orapred0 (prednisolone sodium phosphate oral solution) and Orapred ODT, is prescribed primarily for acute exacerbations of asthma in children, according to a news release.

The Orapred product line is also used to control severe, persistent asthma and to reduce inflammation seen in numerous medical conditions including arthritis and cancer.

Novato, Calif.-based BioMarin develops biopharmaceuticals for serious diseases and medical conditions.

Alliant is a privately held pediatric specialty pharmaceutical company located in Alpharetta, Ga.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.